Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Guercio, Brendan J., Sui Zhang, Fang-Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, et al. “IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.” Jnci Cancer Spectr 5, no. 1 (February 2021). https://doi.org/10.1093/jncics/pkaa074.

PMID
33426464
Full Text

Geyer, Susan Michelle, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Sanja Karovic, Michael V. Knopp, Priya Kumthekar, et al. “Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.” In Journal of Clinical Oncology, 39:361–361. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.361.

Full Text

Dercle, Laurent, Susan Michelle Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Lyndon Luk, et al. “Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).” In Journal of Clinical Oncology, 39:343–343. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.343.

Full Text

El Dika, Imane H., Susan Michelle Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Amin Yaqubie, et al. “Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).” In Journal of Clinical Oncology, 39:325–325. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.325.

Full Text

Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, et al. “A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.” Plos One 16, no. 6 (2021): e0252995. https://doi.org/10.1371/journal.pone.0252995.

PMID
34170918
Full Text

Liu, Yingmiao, Madelon Paauwe, Andrew B. Nixon, and Lukas J. A. C. Hawinkels. “Endoglin Targeting: Lessons Learned and Questions That Remain.” Int J Mol Sci 22, no. 1 (December 25, 2020). https://doi.org/10.3390/ijms22010147.

PMID
33375670
Full Text

Mackintosh, Christopher, Chen Yuan, Fang-Shu Ou, Sui Zhang, Donna Niedzwiecki, I-Wen Chang, Bert H. O’Neil, et al. “Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.” Jama Oncol 6, no. 11 (November 1, 2020): 1713–21. https://doi.org/10.1001/jamaoncol.2020.3938.

PMID
32940631
Full Text

Liu, Yingmiao, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, et al. “Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.” Mol Cancer Ther 19, no. 10 (October 2020): 2146–54. https://doi.org/10.1158/1535-7163.MCT-20-0249.

PMID
32747417
Full Text

Gaillard, S., G. Broadwater, W. S. Andrews, M. D. Starr, R. A. Previs, L. J. Havrilesky, B. A. Davidson, et al. “Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers.” In Gynecologic Oncology, 159:41–41. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.087.

Full Text

Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.” Clin Cancer Res 26, no. 16 (August 15, 2020): 4268–79. https://doi.org/10.1158/1078-0432.CCR-20-0056.

PMID
32398324
Full Text

Pages